Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination

Lancet. 2021 May 15;397(10287):1842. doi: 10.1016/S0140-6736(21)00871-0. Epub 2021 Apr 14.

Authors

Viktoria Muster¹, Thomas Gary², Reinhard B Raggam¹, Albert Wölfler³, Marianne Brodmann¹

Affiliations

¹ Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
² Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Electronic address: thomas.gary@medunigraz.at.
³ Department of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

PMID: 33864749
DOI: 10.1016/S0140-6736(21)00871-0

No abstract available

Publication types

Case Reports

MeSH terms

Anticoagulants / therapeutic use
Antithrombins / therapeutic use
COVID-19 Vaccines / adverse effects*
ChAdOx1 nCoV-19
Dabigatran / therapeutic use
Female
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Middle Aged
Pulmonary Embolism / chemically induced*
Pulmonary Embolism / diagnostic imaging
Pulmonary Embolism / drug therapy
Thrombocytopenia / chemically induced*
Thrombocytopenia / diagnostic imaging
Thrombocytopenia / drug therapy

Substances

Anticoagulants
Antithrombins
COVID-19 Vaccines
Heparin, Low-Molecular-Weight
ChAdOx1 nCoV-19
Dabigatran